About Event
We Discovered & Shaped the Future of Biologics & Antibody Therapies at the 4th Fc-Mediated Function Summit
At the intersection of groundbreaking research, clinical innovation, and collaborative networking, the 4th Fc-Mediated Function Summit stood as a beacon for advancing the frontier of FcRn, FcγR, and IgG therapeutics. Our mission was to supercharge molecular development, elevate clinical utility, and explore novel therapeutic applications through a comprehensive understanding of targets and biology.
In a landscape where clinical data was expanding, and partnerships like the Argenx-Genmab powerhouse exemplified the potential of antibody therapies, the spotlight on biologics Fc modulation as a therapeutic target had been more intense than ever. The 4th Fc-Mediated Function Summit continued to be at the forefront of this movement, uniting experts and enthusiasts alike.
2024 Program Highlights:
Download the Full 2024 Program for more information on:
-
- 17+ Fc-Therapeutic Industry Expert Speakers
- 17+ Ground-breaking Sessions
- 8+ Hours of Industry Networking
- & Much More!
What Did 2024 Offer?
This was the only platform providing a complete overview of FcRn, bringing together FcRn and FcγR target biology with molecular engineering and real-world clinical outcomes. This exclusivity ensured that attendees could dive deep into the intricacies of Fc modulation, gaining insights that are unparalleled in both breadth and depth.
Attendees joined 60+ peers from diverse fields including immunology, antibody engineering, pharmacology, toxicology, and immuno-oncology for three unrivaled days of content. This was the definitive and only forum exclusively dedicated to targeting FcRn, FcγR, and novel Fc optimization.
Participants shaped the future and become part of a community that values collaboration, innovation, and the relentless pursuit of therapeutic excellence. Together, they were at the forefront of scientific progress in checkpoint agonism, gained cross-disease insights into Fc manipulation in oncology, and witnessed first-hand presentations from esteemed speakers shaping the future of antibody therapies.